Short Interest in InspireMD Inc (NSPR) Drops By 26.2%

InspireMD Inc (NYSEAMERICAN:NSPR) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,380,239 shares, a decline of 26.2% from the December 14th total of 1,869,651 shares. Based on an average daily trading volume, of 732,618 shares, the days-to-cover ratio is presently 1.9 days. Currently, 3.9% of the company’s stock are short sold.

Shares of NYSEAMERICAN:NSPR opened at $0.18 on Friday. InspireMD has a 12-month low of $0.13 and a 12-month high of $9.17.

InspireMD (NYSEAMERICAN:NSPR) last announced its quarterly earnings data on Tuesday, November 6th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter. The business had revenue of $0.77 million during the quarter.

COPYRIGHT VIOLATION WARNING: This piece was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2019/01/11/short-interest-in-inspiremd-inc-nspr-drops-by-26-2.html.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.

Read More: How to Invest in a Bull Market

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply